Viatris Inc. (VTRS)
Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US DOJ drops Viatris unit Mylan from industry-wide antitrust probe
Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.
Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM ET Company Participants Scott Smith - CEO Theodora Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Why don't we get started?
Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Jefferies 2024 Global Healthcare Conference Call June 6, 2024 8:00 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Well, good morning, everybody.
Viatris: Skeptics Proven Right Once Again
Viatris Inc. reported Q1 2024 results in line with expectations, with a 2% decline in net sales. The company's EBITDA and free cash flow have been negatively impacted by declining sales, and its debt to EBITDA ratio remains high. Despite the low P/E ratio, Viatris stock has not delivered significant returns. We go into the reasons why.
